- Home
- KORE vs NRXP Comparison
KORE vs NRXP Comparison
Compare KORE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KORE
- NRXP
- Stock Information
- Founded
- KORE 2003
- NRXP 2015
- Country
- KORE United States
- NRXP United States
- Employees
- KORE N/A
- NRXP N/A
- Industry
- KORE Telecommunications Equipment
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- KORE Consumer Discretionary
- NRXP Health Care
- Exchange
- KORE Nasdaq
- NRXP Nasdaq
- Market Cap
- KORE 39.3M
- NRXP 32.6M
- IPO Year
- KORE N/A
- NRXP N/A
- Fundamental
- Price
- KORE $2.35
- NRXP $3.24
- Analyst Decision
- KORE Hold
- NRXP Strong Buy
- Analyst Count
- KORE 2
- NRXP 4
- Target Price
- KORE $2.75
- NRXP $28.50
- AVG Volume (30 Days)
- KORE 14.4K
- NRXP 298.7K
- Earning Date
- KORE 08-14-2025
- NRXP 08-13-2025
- Dividend Yield
- KORE N/A
- NRXP N/A
- EPS Growth
- KORE N/A
- NRXP N/A
- EPS
- KORE N/A
- NRXP N/A
- Revenue
- KORE $282,254,000.00
- NRXP N/A
- Revenue This Year
- KORE $4.66
- NRXP N/A
- Revenue Next Year
- KORE $6.71
- NRXP N/A
- P/E Ratio
- KORE N/A
- NRXP N/A
- Revenue Growth
- KORE N/A
- NRXP N/A
- 52 Week Low
- KORE $1.10
- NRXP $1.10
- 52 Week High
- KORE $4.88
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- KORE 47.32
- NRXP 55.25
- Support Level
- KORE $2.20
- NRXP $2.90
- Resistance Level
- KORE $2.48
- NRXP $3.53
- Average True Range (ATR)
- KORE 0.19
- NRXP 0.24
- MACD
- KORE -0.01
- NRXP -0.04
- Stochastic Oscillator
- KORE 51.61
- NRXP 40.00
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.